Acadian Asset Management LLC decreased its position in ICON PLC (NASDAQ:ICLR) by 1.1% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,186,218 shares of the medical research company’s stock after selling 24,055 shares during the period. ICON PLC accounts for about 1.0% of Acadian Asset Management LLC’s portfolio, making the stock its 21st largest position. Acadian Asset Management LLC’s holdings in ICON PLC were worth $213,792,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Somerset Trust Co boosted its stake in ICON PLC by 0.4% in the first quarter. Somerset Trust Co now owns 5,638 shares of the medical research company’s stock worth $449,000 after buying an additional 24 shares during the last quarter. IFP Advisors Inc boosted its stake in ICON PLC by 2.7% in the first quarter. IFP Advisors Inc now owns 2,232 shares of the medical research company’s stock worth $178,000 after buying an additional 59 shares during the last quarter. World Asset Management Inc boosted its stake in ICON PLC by 1.8% in the first quarter. World Asset Management Inc now owns 3,455 shares of the medical research company’s stock worth $275,000 after buying an additional 60 shares during the last quarter. Huntington National Bank boosted its stake in ICON PLC by 5.0% in the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after buying an additional 77 shares during the last quarter. Finally, Sawtooth Solutions LLC boosted its stake in ICON PLC by 1.0% in the first quarter. Sawtooth Solutions LLC now owns 10,556 shares of the medical research company’s stock worth $842,000 after buying an additional 102 shares during the last quarter. 92.61% of the stock is owned by institutional investors.
ICON PLC (NASDAQ ICLR) opened at 99.47 on Thursday. The firm has a market cap of $5.35 billion, a PE ratio of 20.65 and a beta of 0.59. The company has a 50-day moving average price of $97.54 and a 200-day moving average price of $87.14. ICON PLC has a one year low of $72.70 and a one year high of $101.40.
ICON PLC (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.01. The company had revenue of $431 million during the quarter, compared to analyst estimates of $430.68 million. ICON PLC had a net margin of 16.15% and a return on equity of 28.89%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $1.14 earnings per share. Equities analysts predict that ICON PLC will post $5.17 earnings per share for the current fiscal year.
WARNING: This article was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/07/27/acadian-asset-management-llc-sells-24055-shares-of-icon-plc-nasdaqiclr.html.
A number of research firms have weighed in on ICLR. Jefferies Group LLC reaffirmed a “hold” rating on shares of ICON PLC in a research report on Thursday, May 11th. Evercore ISI increased their target price on ICON PLC from $91.50 to $92.00 and gave the stock an “outperform” rating in a research note on Friday, April 28th. Robert W. Baird cut their target price on ICON PLC from $107.00 to $97.00 and set an “outperform” rating for the company in a research note on Friday, June 9th. Goldman Sachs Group, Inc. (The) raised ICON PLC from a “buy” rating to a “conviction-buy” rating and set a $117.00 price objective for the company in a research note on Friday, July 7th. Finally, Zacks Investment Research raised ICON PLC from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Tuesday, June 27th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $96.00.
ICON PLC Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICON PLC (NASDAQ:ICLR).
Receive News & Ratings for ICON PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON PLC and related companies with MarketBeat.com's FREE daily email newsletter.
